Radiopharmaceuticals are transforming the oncology landscape, offering new pathways for precision treatment and improved patient outcomes. Yet, designing and executing clinical trials for these complex therapies requires navigating unique regulatory, operational, and quality assurance challenges.

Join IQVIA’s experts for an in-depth discussion on how to optimize radiopharmaceutical trials—from aligning with FDA’s latest guidance on dosage optimization and overcoming logistical hurdles, to planning for the post-approval phase to ensure therapies reach patients reliably, safely and at scale. Learn how IQVIA’s proven expertise and global capabilities can help accelerate your oncology pipeline and bring novel therapeutic modalities to market faster.

Three key take-aways

• Gain actionable insights on regulatory trends and trial optimization.
• Learn how to mitigate operational risks in radiopharmaceutical studies.
• Understand how IQVIA’s expertise accelerates oncology innovation.

Speakers:

David Alsadius, MD, PhD
Senior Medical Director, Solid Tumor Lead, Hematology-Oncology Center of Excellence, IQVIA

Michael Armstrong, MD, PhD
Senior Director, Medical, Hematology-Oncology Center of Excellence, IQVIA Biotech

Michael Brave, MD
Vice President, Therapeutic and Regulatory Strategy, IQVIA

Carsten Henke
Client Partner, IQVIA

Amanda Potocky
Director, Clinical Project Management, Immuno-Oncology and Cell and Gene Therapy Oncology, IQVIA Biotech

For more information and to register, click here.